{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:31:26Z","timestamp":1758637886508},"reference-count":24,"publisher":"Centers for Disease Control MMWR Office","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6714a4","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T10:15:42Z","timestamp":1523528142000},"page":"424-431","source":"Crossref","is-referenced-by-count":18,"title":["Updated CDC Recommendations for Using Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria in Pregnant Women in the United States"],"prefix":"10.15585","volume":"67","author":[{"given":"Sarah-Blythe","family":"Ballard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Salinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"MPHc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Arguin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghna","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrine R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6224","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R1","unstructured":"CDC. Guidelines for treatment of malaria in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. https:\/\/www.cdc.gov\/malaria\/resources\/pdf\/treatmenttable.pdf"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R2","unstructured":"World Health Organization Malaria Policy Advisory Committee. Intermittent screening and treatment in pregnancy and the safety of ACTs in the first trimester. Geneva, Switzerland: World Health Organization; 2015. http:\/\/www.who.int\/malaria\/publications\/atoz\/istp-and-act-in-pregnancy.pdf?ua=1"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R3","unstructured":"World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva, Switzerland: World Health Organization; 2015."},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss6612a1","article-title":"Malaria surveillance\u2014United States, 2014.","volume":"66","author":"Mace","year":"2017","journal-title":"MMWR Surveill Summ"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R5","doi-asserted-by":"publisher","first-page":"ofv170","DOI":"10.1093\/ofid\/ofv170","article-title":"Artemisinin-based combination therapy versus quinine or other combinations for treatment of uncomplicated Plasmodium falciparum malaria in the second and third trimester of pregnancy: a systematic review and meta-analysis.","volume":"3","author":"Burger","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0035-9203(00)90235-9","article-title":"Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy.","volume":"94","author":"McGready","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R7","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1086\/324349","article-title":"Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum.","volume":"33","author":"McGready","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1086\/432551","article-title":"A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy.","volume":"192","author":"McGready","year":"2005","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1473-3099(10)70202-4","article-title":"Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial.","volume":"10","author":"Piola","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3855\/T2.2.135","article-title":"A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda.","volume":"2","author":"Kaye","year":"2008","journal-title":"J Infect Dev Ctries"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R11","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1128\/AAC.02595-14","article-title":"Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.","volume":"58","author":"Mosha","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R12","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1128\/AAC.01605-15","article-title":"Artemether-lumefantrine pharmacokinetics and clinical response are minimally altered in pregnant Ugandan women treated for uncomplicated falciparum malaria.","volume":"60","author":"Nyunt","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00228-006-0199-7","article-title":"The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.","volume":"62","author":"McGready","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R14","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1128\/AAC.00195-09","article-title":"Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.","volume":"53","author":"Tarning","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R15","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1086\/503423","article-title":"Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria.","volume":"42","author":"Price","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R16","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1508606","article-title":"Four artemisinin-based treatments in African pregnant women with malaria.","volume":"374","author":"PREGACT Study Group","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijgo.2015.05.009","article-title":"A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in pregnancy.","volume":"131","author":"Ukah","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R18","doi-asserted-by":"crossref","unstructured":"McGready R, Tan SO, Ashley EA,  A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med 2008;5:e253.","DOI":"10.1371\/journal.pmed.0050253"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/01443619867038","article-title":"Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine\/sufadoxine-pyrimethamine-resistant falciparum malaria during pregnancy.","volume":"18","author":"Sowunmi","year":"1998","journal-title":"J Obstet Gynaecol"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1475-2875-9-249","article-title":"Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia.","volume":"9","author":"Manyando","year":"2010","journal-title":"Malar J"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R21","doi-asserted-by":"crossref","unstructured":"Kovacs SD, van Eijk AM, Sevene E,  The safety of artemisinin derivatives for the treatment of malaria in the 2nd or 3rd trimester of pregnancy: a systematic review and meta-analysis. PLoS One 2016;11:e0164963.","DOI":"10.1371\/journal.pone.0164963"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R22","doi-asserted-by":"crossref","unstructured":"Dellicour S, Sevene E, McGready R,  First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies. PLoS Med 2017;14:e1002290.","DOI":"10.1371\/journal.pmed.1002290"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/1475-2875-11-328","article-title":"Management of imported malaria in Europe.","volume":"11","author":"Askling","year":"2012","journal-title":"Malar J"},{"key":"key-10.15585\/mmwr.mm6714a4-201804121015-R24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jinf.2016.02.001","article-title":"UK malaria treatment guidelines 2016.","volume":"72","author":"Lalloo","year":"2016","journal-title":"J Infect"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T10:16:13Z","timestamp":1523528173000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6714a4.htm?s_cid=mm6714a4_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":24,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2018,4,13]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6714a4","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"type":"print","value":"0149-2195"},{"type":"electronic","value":"1545-861X"}],"subject":[],"published-other":{"date-parts":[[2018,4,13]]},"published":{"date-parts":[[2018,4,13]]}}}